MSTX implements 1:70 reverse split to consummate previously announced reverse merger with SVRA: https://finance.yahoo.com/news/mast-therapeutics-savara-announce-anticipated-120000456.html Existing MSTX shareholders will own 23% of the equity in the new company, slightly lower than from the 24% figure in the Jan 2017 PR (#msg-127699319).